Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stanton Longenecker

Sports Medicine Jacksonville, FL Medical Doctor

NPI 1821092271 CMS profile 309062

2 Shircliff Way Ste 300, Credentialing Department, Jacksonville, FL 32204

Open in the dashboard

General payments

$330,364

111 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stanton Longenecker of Jacksonville, FL is reported in the CMS Open Payments database as having received $330,364 across 111 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $164 4
2024 General $1,085 4
2023 General $8,589 13
2022 General $4,764 12
2021 General $88,176 21
2020 General $120,616 24
2019 General $106,971 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stanton Longenecker
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Stanton Longenecker were reported at $164. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Stanton Longenecker Sports Medicine median Middle half National median
2019 $106,971 $1,176 $199–$4,249 $163
2020 $120,616 $708 $96–$2,890 $114
2021 $88,176 $1,213 $152–$3,994 $132
2022 $4,764 $1,230 $159–$3,998 $149
2023 $8,589 $584 $146–$2,836 $160
2024 $1,085 $628 $163–$3,168 $164
2025 $164 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Encore Medical, LP $273,661 11 payments
  2. Uoc USA Inc $52,618 44 payments
  3. Medacta USA, Inc. $1,699 5 payments
  4. NextStep Arthropedix, LLC $728 2 payments
  5. Pfizer Inc. $381 17 payments
  6. Maxx Orthopedics, Inc. $233 2 payments
  7. Total Joint Orthopedics, Inc. $139 1 payment
  8. Vericel Corporation $129 2 payments
  9. Biocomposites Inc $126 4 payments
  10. Anika Therapeutics, Inc. $101 1 payment
  11. Other $550 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $273,661 11 payments
  2. Consulting Fee $51,000 25 payments
  3. Food and Beverage $3,566 71 payments
  4. Travel and Lodging $2,138 4 payments
Products named General payments · program years 2019–2025
  1. DJO Surgical TaperFill Hip System Joint Implants $200,086 8 payments
  2. DJO Surgical TaperFill Hip System Joint Implants $73,574 3 payments
  3. U-Motion II, UTF $14,000 6 payments
  4. U2 United Knee System $12,326 8 payments
  5. U-Motion II, U2 UOC Hip and Knee Systems $9,500 2 payments
  6. U2 Knee $5,000 3 payments
  7. U-Motion II, U2 UOC Hip and Knee System $4,000 2 payments
  8. U2 UOC Knee System $3,973 11 payments
  9. AMISTEM $1,699 5 payments
  10. U-Motion II $1,500 1 payment
  11. Other $4,982 71 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$30,762

Of which drugs: $10,678

Medicare patients

144

Average age 77

Services billed

982

94 women, 50 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 39%
Chronic kidney disease 33%
Ischemic heart disease 31%
Atrial fibrillation 24%
Depression 24%
Cancer 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, monovisc, for intra-articular injection, per dose J7327 Office 14 19 $10,222
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 62 620 $456

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • PFIZER INC. $46
$46 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

111 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record